Coston McIsaac & Partners’s GSK GSK Stock Holding History

Coston McIsaac & Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72K	Buy	1,381 +20	+1%	+$1.06K	0.01%	279
2026 Q1	$75K	Sell	1,361 -34	-2%	-$1.84K	0.02%	259
2025 Q4	$68K	Buy	1,395 +206	+17%	+$9.61K	0.02%	270
2025 Q3	$51K	Hold	1,189	–	–	0.01%	303
2025 Q2	$45K	Hold	1,189	–	–	0.01%	316
2025 Q1	$46K	Hold	1,189	–	–	0.01%	282
2024 Q4	$40K	Hold	1,189	–	–	0.01%	311
2024 Q3	$48	Hold	1,189	–	–	0.01%	284
2024 Q2	$45K	Hold	1,189	–	–	0.01%	276
2024 Q1	$50K	Hold	1,189	–	–	0.02%	267
2023 Q4	$44K	Hold	1,189	–	–	0.02%	279
2023 Q3	$43K	Hold	1,189	–	–	0.02%	257
2023 Q2	$42K	Hold	1,189	–	–	0.01%	296
2023 Q1	$42K	Hold	1,189	–	–	0.02%	289
2022 Q4	$41	Hold	1,189	–	–	0.02%	298
2022 Q3	$34K	Buy	1,189 +2	+0.2%	+$76	0.02%	273
2022 Q2	$65K	Buy	+1,187	New	+$65.5K	0.04%	117

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Coston McIsaac & Partners's GSK Position: Q2 2026 in Review

Coston McIsaac & Partners increased its GSK (GSK) stake by 1.5% in Q2 2026, buying an estimated $1.06K and bringing the position to 1,381 shares worth $72K. The position accounts for 0.01% of the portfolio, ranked #279.

Coston McIsaac & Partners first reported a position in GSK in Q2 2022 and has held it in 17 quarters since. The position peaked at $75K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Coston McIsaac & Partners held 1,381 shares of GSK worth $72K as of Q2 2026.
Coston McIsaac & Partners bought 20 GSK shares in Q2 2026, an estimated $1.06K.
GSK made up 0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #279 holding.
Coston McIsaac & Partners first reported a position in GSK in Q2 2022 and has held it in 17 quarters since.
Coston McIsaac & Partners's GSK position peaked at $75K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.